As noted, however, no significant difference in overall survival was seen between the groups, with a median survival period for each of about 26 months.
然而，正如已经提到的，在各组之间没有看到总体存活率的显著性差异，中值存活期分别为约26个月。
The prognosis is poor with a median survival of 6 to12 months (similar to GBM). Local recurrence is typical, with extracranial metastases being common.
预后较差，平均生存时间是6- 12个月(类似于gbm)。局部复发及颅外转移常见。
Study of a further 124 French patients showed that those deemed at good risk using the model, had a median survival of 378 days, compared to 90 days in the poor risk group.
对124名法国患者的进一步研究提示，运用该模型，认为无风险的患者中位生存期为378天，有风险的只有90天。
Amyloid cardiomyopathy is largely unresponsive to current heart failure therapies and is associated with a median survival of less than 6 months and a 5-year survival of less than 10%.
淀粉样变心肌病对目前的心衰治疗多无反应，其中位生存期小于6个月，5年存活率小于10%。
Then, a median period of recurrence and survival was reckoned.
计算术后中位数复发和中位数生存时间。
Methods a mouse model of disseminated candidiasis was established and the survival rate and median survival time after administration of agent were detected.
方法建立小鼠系统性白念珠菌感染模型，观察给药后小鼠中位生存时间，并检测给药后小鼠肾脏菌落形成单位计数。
But median overall survival, a secondary end point, was 20.5 months in the combination group and 20.6 months in the monotherapy group.
但中位总生存期，次要观察终点，联合组为20.5个月，而单药治疗组为20.6个月。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。
After a median follow-up of 35.8 months, 80 patients experienced metastatic or recurrent tumors and 40 patients died. The median overall survival was not reached and the median DFS was 24.1 months.
所有患者中位随访时间35.8个月，80例出现复发或转移，40例死亡，中位生存期未达到，中位无疾病生存期（DFS）为24.1个月。
With a median follow-up of 30 months, Loma Linda researchers reported three-year local control and disease-specific survival rates of 74% and 72% respectively.
中位随访30个月，美国罗马琳达研究报告3年局部控制和特定疾病存活率为74 ％和72 ％分别。
With a median follow-up of 30 months, Loma Linda researchers reported three-year local control and disease-specific survival rates of 74% and 72% respectively.
中位随访30个月，美国罗马琳达研究报告3年局部控制和特定疾病存活率为74 ％和72 ％分别。
应用推荐